Skip to main content
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Nov;74(9):1342–1348. doi: 10.1038/bjc.1996.547

32P-post-labelling analysis of DNA adducts formed in the upper gastrointestinal tissue of mice fed bracken extract or bracken spores.

A C Povey 1, D Potter 1, P J O'Connor 1
PMCID: PMC2074780  PMID: 8912527

Abstract

Bracken toxicity to both domestic and laboratory animals is well established and tumours are formed when rodents are treated with either bracken extracts or bracken spores. In this study we have administered bracken spores and extract to mice in order to investigate whether such exposure leads to the formation of DNA adducts. DNA, isolated from the upper gastrointestinal tract and liver, was digested to 3'-nucleotides. Adducts were extracted with butanol, 32P-post-labelled, separated by thin layer chromatography (TLC) and visualised and quantified using storage-phosphor technology. A cluster of adducts was clearly seen in the DNA of the upper gastrointestinal tract, but not liver, 5 and 24 h after treatment with bracken extract or bracken spores. These adducts were not observed in DNA extracted from vehicle-treated animals. Whereas, after 5 h adduct levels in extract and spore-treated animals were similar, after 24 h adduct levels in the extract-treated animals had diminished by > 75%, but levels in spore-treated animals remained similar to those found after 5 h. This suggests that the DNA-reactive compounds were being released slowly from the spores, even though the spores had been sonicated before administration. Adducts were also quantified after the addition of an internal standard (deoxyinosine 3'-monophosphate) by comparing the amount of label incorporated into the adducts with that found in a known amount of the internal standard. Adduct levels using this internal standard approach were similar to those found by direct measurement of radioactivity incorporated into the adduct, indicating that the labelling of adducts was quantitative. We have tried, unsuccessfully, to synthesise ptaquiloside, the principal carcinogenic component present within bracken. However, similar patterns of adducts were observed when two other compounds, (1-(4-chlorophenyl sulphonyl)-l-cyclopropane carbonitrile and 3-cyclopropylindeno [1,2-c] pyrazol-4-(O-methyl)oxime), which both contain a cyclopropyl ring, were administered to mice. The adducts detected in bracken-treated animals may, thus, have arisen from ptaquiloside but, whether these adducts arise directly from the compounds and bracken spores/extract themselves or via an indirect mechanism, remains to be determined. As bracken-induced DNA adducts are detectable in rodent tissues by a 32P-post-labelling procedure commonly employed to investigate DNA damage in human populations, it may prove possible to apply such approaches to determine human exposure.

Full text

PDF
1342

Images in this article

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beach A. C., Gupta R. C. Human biomonitoring and the 32P-postlabeling assay. Carcinogenesis. 1992 Jul;13(7):1053–1074. doi: 10.1093/carcin/13.7.1053. [DOI] [PubMed] [Google Scholar]
  2. Cooper D. P., Griffin K. A., Povey A. C. Immunoaffinity purification combined with 32P-postlabelling for the detection of O6-methylguanine in DNA from human tissues. Carcinogenesis. 1992 Mar;13(3):469–475. doi: 10.1093/carcin/13.3.469. [DOI] [PubMed] [Google Scholar]
  3. Evans I. A., Mason J. Carcinogenic activity of bracken. Nature. 1965 Nov 27;208(5013):913–914. doi: 10.1038/208913a0. [DOI] [PubMed] [Google Scholar]
  4. Galpin O. P., Whitaker C. J., Whitaker R., Kassab J. Y. Gastric cancer in Gwynedd. Possible links with bracken. Br J Cancer. 1990 May;61(5):737–740. doi: 10.1038/bjc.1990.165. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Gupta R. C. Enhanced sensitivity of 32P-postlabeling analysis of aromatic carcinogen:DNA adducts. Cancer Res. 1985 Nov;45(11 Pt 2):5656–5662. [PubMed] [Google Scholar]
  6. Haque K., Cooper D. P., Povey A. C. Optimization of 32P-postlabelling assays for the quantitation of O6-methyl and N7-methyldeoxyguanosine-3'-monophosphates in human DNA. Carcinogenesis. 1994 Nov;15(11):2485–2490. doi: 10.1093/carcin/15.11.2485. [DOI] [PubMed] [Google Scholar]
  7. Hirono I. Carcinogenicity of plant constituents: pyrrolizidine alkaloids, flavonoids, bracken fern. Prog Clin Biol Res. 1986;206:45–53. [PubMed] [Google Scholar]
  8. Hirono I., Ogino H., Fujimoto M., Yamada K., Yoshida Y., Ikagawa M., Okumura M. Induction of tumors in ACI rats given a diet containing ptaquiloside, a bracken carcinogen. J Natl Cancer Inst. 1987 Nov;79(5):1143–1149. [PubMed] [Google Scholar]
  9. Koivisto P., Hemminki K. 32P-postlabelling of 2-hydroxyethylated, ethylated and methylated adducts of 2'-deoxyguanosine 3'-monophosphate. Carcinogenesis. 1990 Aug;11(8):1389–1392. doi: 10.1093/carcin/11.8.1389. [DOI] [PubMed] [Google Scholar]
  10. Povey A. C., Cooper D. P. The development, validation and application of a 32P-postlabelling assay to quantify O6-methylguanine in human DNA. Carcinogenesis. 1995 Jul;16(7):1665–1669. doi: 10.1093/carcin/16.7.1665. [DOI] [PubMed] [Google Scholar]
  11. Randerath K., Reddy M. V., Disher R. M. Age- and tissue-related DNA modifications in untreated rats: detection by 32P-postlabeling assay and possible significance for spontaneous tumor induction and aging. Carcinogenesis. 1986 Sep;7(9):1615–1617. doi: 10.1093/carcin/7.9.1615. [DOI] [PubMed] [Google Scholar]
  12. Saffhill R., Margison G. P., O'Connor P. J. Mechanisms of carcinogenesis induced by alkylating agents. Biochim Biophys Acta. 1985 Dec 17;823(2):111–145. doi: 10.1016/0304-419x(85)90009-5. [DOI] [PubMed] [Google Scholar]
  13. Shields P. G., Harris C. C., Petruzzelli S., Bowman E. D., Weston A. Standardization of the 32P-postlabeling assay for polycyclic aromatic hydrocarbon-DNA adducts. Mutagenesis. 1993 Mar;8(2):121–126. doi: 10.1093/mutage/8.2.121. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES